The Magnum Group

The Leader In Vision Care Business Development

TEL: 415.453.5550 |
1000 Fourth Street, Suite 225 San Rafael, CA 94901 USA

Current Clients

The Magnum Group, Inc. works with a variety of ophthalmic technologies and companies. Some are seeking licensing agreements or financing; others are searching for Strategic Partners or acquisitions. These include intraocular, contact and spectacle lenses, refractive surgery, vitreoretinal, capital and diagnostic equipment, and e-commerce. The following are brief summaries of Magnum's current Client technologies. In most cases, additional information is available on Client companies in the form of Executive Summaries, PowerPoint Presentations and Business Plans. (Former Clients and technologies are shown as Previous Clients). The information below on companies and their technologies is deemed to be reliable, but cannot be guaranteed.

  Select a Briefcase or Scroll Below to View Details
  box ELENZA, INC.Electronic Intraocular Lens for the Treatment of Presbyopia case
  box ESTEVE GROUPSeeking to Acquire Bio-Pharma & Device Companies case
  box EYE-LENS PTE LTDAsian Ophthalmic Distributor case
  box IMPLANDATA OPHTHALMIC PRODUCTS GmbHTransforming Glaucoma Care via Advanced
Electronic Intraocular Pressure Monitoring
  box LEGRANDEPersonalized Rx/OTC Subscription Service case
  box LENTICULAR RESEARCH GROUP, LLCTreatment for Presbyopia case
  box SEECARE TECHNOLOGIES, LLCDesktop/Head-Mounted, Patient-Directed Retinal Imaging Technology case
  box TRUEVISION SYSTEMS, INC.3D Augmented Reality Live Video Surgery case
  box VISTA OCULAR LLCElectronic Enhancement for Presbyopia Correcting Lenses case


    Eye Lens

Elenza, Inc.Electronic Intraocular Lens for the Treatment of Presbyopia

ELENZA, Inc. (ELENZA) is a pre-clinical stage Company developing the world’s first Auto-Focal Presbyopia-correcting Intraocular Lens (IOL) to compete in the multi-billion dollar IOL market for the correction of near, intermediate and distance vision. ELENZA’s electro-active IOL uses a proprietary combination of liquid-crystal chemistry, re-chargeable electrical power, and integrated-circuitry to create a smart optic, which will provide patients with the ability to see more clearly and naturally in all light conditions and over the entire range of vision, switching from far vision to near vision in milliseconds. The proprietary IOL is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life. The reprogrammable proprietary algorithm used for switching the lens from far to near vision has been tested in a clinical study to greater than 99% accuracy in the auto-focal mode of operation. The lens can also be manually controlled by the patient. Unlike mechanical and multi-focal IOL’s, the ELENZA-IOL has been designed to provide reproducible outcomes for all patients, regardless of age or intraocular physiology.

Auto Focal IOLELENZA has an extensive intellectual property portfolio consisting of 20 patent families (~70 individual issued and pending patents) plus numerous trade secrets relating to intraocular devices. Technology covered by patents includes optics, electronics, hermetic sealing, microchips, physiological trigger, RF communication and power management. In addition, ELENZA has assembled a “best-in-class” team of contract engineering and manufacturing providers (primarily in Europe) to design and manufacture the Company’s Sapphire™ Auto-Focal IOL.

In 2013, following a funding and development collaboration with Alcon, a Novartis Division, a dispute arose between the parties and ELENZA was forced into an operational hibernation during which the Company suspended its development activities while continuing to prosecute its IP portfolio. The disengagement from Alcon was completed in 2017. At the time operations were suspended, ELENZA had effectively achieved design-freeze on its first-generation product and was six-nine months from first-in-man clinical studies in Europe.

ELENZA has engaged The Magnum Group, Inc. ( to assist the Company to identify a partner to acquire its assets or sponsor a re-start with an option to acquire the Company and/or complete a technology transfer to a new entity.

Back To Top



Esteve Group—The Esteve Group (Esteve) seeks to acquire one or more US pharmaceutical and/or device companies to further expand their growing ophthalmology business. Based in Barcelona, Esteve is strategically active in three areas: Active Pharmaceutical Ingredient (API) manufacturing, Generics, and Branded Pharmaceuticals. Esteve’s business generated more than €800M in 2016 net sales, its Pharmaceutical business leads the Spanish market and its API and Generics businesses have significant international footprints.

Esteve's strong ophthalmology business, which is backed by a robust and experienced organization, sells both pharmaceuticals and surgical device products. Esteve is focused on growing its list of proprietary products and expanding the regions in which these innovative products are sold. Further, Esteve has an experienced R&D group with a €95M budget to fund novel and proprietary products in ophthalmology and other specialties

Esteve’s management team, led by former Alcon executive Joesph Sullivan, plans to significantly grow their ophthalmic business, with a focus on the US market, both through internal R&D and by acquiring significant businesses to catalyze this growth.

Esteve chart

Back To Top


    Eye Lens

EYE-LENS PTE LTDAsian Ophthalmic Distributor

Eye-Lens Pte Ltd (Eye Lens) is a distributor of ophthalmic products active in the Asian markets, particularly in Japan and Singapore. Since being established in 2003 by Mr. Jun Torihata, former President of Pharmacia Ophthalmics, Japan., Eye-Lens has assembled a team of multi-disciplinary professionals, working together to achieve one goal—helping our partners to grow their business. With a physical presence in both Japan and Singapore, Eye-Lens is utilizing a large team of highly specialized sales people, application specialists and service engineers, ensuring the best pre- and post-sale service to our customer’s support

Through its insights into the Japanese and Asia-Pacific markets, Eye-Lens has established strong networks in academic, research and healthcare institutions, government and private organizations, doctors and medical professionals, as well as partnerships with leading companies in the ophthalmic industry. Our close relations with the Shinagawa Group—the largest refractive center in the world is an asset that benefits many of our partners leveraging on their high patient volume for generating sales as well as valuable clinical data.

Eye-Lens has been successfully distributing and marketing ophthalmic products since its inception, becoming the largest international distributor for many ophthalmic companies, including IntraLase prior to their sale to AMO, and today the following companies are among our partners (in alphabetic order):

  1. Acufocus
  2. Avedro
  3. BioTissue
  4. PRN
  5. Schwind Eye-Tech Solutions
Eye-Lens is a multi-cultural company, bridging not only the language barriers but also the culture barriers (East and West), which is an essential element in developing a successful business in Asia. Our core values are: Professionalism, Vibrancy, Honesty and Integrity.

Eye Lens is seeking innovative products in the refractive and premium cataract domains from companies that are in interested in distribution opportunities in the Asian and Japanese markets, and are looking for cash flow sources and clinical/market data while focusing on developing the US market.

Back To Top



IMPLANDATA OPHTHALMIC PRODUCTS GmbHTransforming Glaucoma Care via Advanced Intraocular Pressure Monitoring

Implandata Ophthalmic Products GmbH (Implandata), is a Hannover, Germany based clinical stage company developing transformative products for the improved care of intraocular pressure related eye diseases. This is accomplished by merging proprietary implantable micro-sensors for telemetric measurement of Intraocular Pressure (IOP) with digital health technology. With its family of products, Implandata addresses medical needs in cataract, glaucoma, corneal and vitreoretinal surgery. Continuous patient IOP monitoring facilitates surveillance of Minimal Invasive Glaucoma Surgery (MIGS) and Sustained Drug Release Devices, personalized medical therapy and improves patient therapy compliance. Simple and reliable measurement of absolute IOP (in mmHg) can be easily performed by the patient at home. IOP data is sent from the patient’s home to a secure data-base, providing actionable information to the eye doctor. Patients can also receive IOP history and trends on a smart-phone app, which additionally reminds patients to take their medications.

Implandata currently has eight employees, led by Max G. Ostermeier, CEO, MBA and Stefan Meyer, CTO, MSc—each with over 15 years of ophthalmic and medical device experience. The Company also works with leading ophthalmologists and prestigious clinical sites in Germany and the USA. Clinical data from 44 patients implanted to date, demonstrates safety and efficacy of the System and provides compelling examples of improved therapy and patient compliance. CE marking is expected in the second half of 2016, followed by a European market launch in 2017. An US IDE pilot study is scheduled to begin in early 2017, followed by PMA studies in 2018 for orphan and non-orphan applications. Reimbursement is expected to follow other predicate devices.

Implandata has a strong competitive edge and owns an extensive Intellectual Property portfolio, containing 17 issued and pending patents, an exclusive university license and a significant assortment of trade secrets. Implandata’s business model includes a combination of selling the implant and renting the patient a home-based diagnostic device with 75% margins. Future products include sensor integration in therapeutic surgical device (e.g., MIGS devices, IOL’s, valves…) and closed loop glaucoma therapeutic devices (drug delivery systems and/or microelectronic-mechanical IOP regulation systems).

Implandata is currently raising a €14m Series C round in order to fund market entry in Europe and Asia, opening up California-based operations for entering the US market and to expand the product use. Existing shareholders are committed to contribute €4 million.

Back To Top



LEGRANDEPersonalized Rx/OTC Subscription Service

LEGRANDE Corporation (LEGRANDE, is an Orange County, CA-based technology company that seamlessly enables your doctor (MD or OD) to provide personalized Rx and OTC eye care treatments directly to the patient's home including prescription (branded, generic, and compound), over-the-counter and other products along with education, custom instructions, email/SMS reminders and ongoing communication. The system saves the practice and patients time and money while providing a great experience.

Initially focusing on dry eye, LASIK and cataract surgery, the eye-care packages are drop shipped to the patient’s home (no going to multiple pharmacies) and are personalized in a subscription model. Key elements that differentiate this business include: highly scalable; priced competitively; capitalizes on the trend towards home delivery; personalized; subscription-based; and major Strategics are already in discussions with LEGRANDE to expand their current distribution.

LEGRANDE was founded in 2016 by Tony Sine, an ophthalmic veteran (Allergan, B+L and Strathspey Crown), and other strong industry team members. LEGRANDE's first eye care package shipped in early 2017.

The Company is seeking distribution and financial partners.

Back To Top


    Lenticular Research Group


Lenticular Research Group, LLC ("LRG") is a Chicago-based Company that is developing a proprietary laser technology for treating the primary cause of presbyopia. LRG has engaged in extensive pre-clinical research relative to the physiology of the human crystalline lens. The Company’s treatment involves targeted in-office laser application to the Germinative zone of the crystalline lens, which selectively inhibits epithelial cell reproduction (alters the growth rate of the lens), arresting the progression of presbyopia as the symptoms first emerge. The treatment concept was developed by George McArdle, OD, and advanced through collaborative work with Jerome Kuszak, Ph. D. and Rebecca Zoloski, Ph. D., world-renowned experts on the Crystalline lens.

LRG has completed initial animal studies, and in April 2015 entered into a Joint Venture Agreement with a large and well-respected ophthalmic company to combine their respective technologies to build a multiphoton laser real time imaging and treatment System to perform advanced animal and early first in human studies over the next ~six months. The Company currently has five granted and five pending patents. LRG has also established an exceptional Medical Advisory Board, including Doctors Dan Durrie, Richard Lindstrom, Louis Probst, Steve Schallhorn, Roger Steinert, Vance Thompson and Bill Trattler.

The Company is seeking to raise $250,000 for ongoing support of the Joint Venture and to provide an adequate reserve fund.

Back To Top



SEECARE TECHNOLOGIES, LLCDesktop/Head-Mounted, Patient-Directed Retinal Imaging Technology

SeeCare Technologies, LLC (SeeCare) is a Salt Lake, Utah based, pre-clinical stage company that is developing a next generation, compact, desktop/head-mounted (about the size of a virtual reality headset), non-mydriatic, affordable, retinal imaging device/system that can be self-administered by the patient or used in an Eyecare Professional office setting. The associated proprietary software will provide a high-resolution, 45+ degree wide retinal image that can be evaluated manually or automatically providing a Green, Yellow, Red readout.

SeeCare is developing the retinal imaging technology for the Vision Care industry with two primary markets:

  1. an in-home subscription model for patients and ECP’s to track therapy compliance, efficacy, and disease progression and,
  2. an in-office retinal screening device for OD/MD and other healthcare provider offices. The Company is also developing technology to work in tandem with other remote digital healthcare formats.

SeeCare was founded in early 2017 by the Invention Science Fund (ISF) of Intellectual Ventures, a privately held company that invents technology and then incubates them into new start-up businesses. Bill Gates is an investor in many of ISF’s spin-out companies. SeeCare has also received grant funding from NASA and is currently developing this technology for the space program. The Company is presently building its team, and is led by Bob Main—a vision care veteran of over 30 years.

SeeCare is seeking strategic and financial partners to complete development and commercialization of this technology.

Back To Top



TRUEVISION SYSTEMS, INC.3D Augmented Reality Live Video Surgery

TrueVision’s Digital Microscope Platform™ replaces an analog optical microscope with integrated 3D visualization, augmented reality and live video technology and is transforming surgical outcomes across specialties. The platform also provides enhanced ergonomics along with a growing number of applications (apps) based on treatment, specialty, and/or surgeon. The Digital Microscope Platform provides best-in-class visualization across multiple modalities including 3D depth of field, extensive magnification ranges, varied surgeon-controlled cameras and angles (including microscope, endoscope or other probe based cameras), varied light, color and fluorescence options and OCT/other medical imaging options. Its augmented reality technology incorporates diagnostic information, 3D reconstructed imagery (e.g., CT/MRI imagery) and surgical guidance in the live surgery video feed.

The Digital Microscope Platform apps include TrueGuide™ providing surgical guidance, TrueFusion™ providing augmented reality technology, and TrueCloud™ providing cloud-based practice-wide data transfer from multiple diagnostics for use on the platform along with future apps to enhance surgical outcomes. TrueVision’s platform reverses the limitations of traditional analog optical microscopes by allowing seamless aggregation of patient data from the multiple diagnostics and digital microscopes throughout the clinic into one repository for use when and where needed. TrueVision’s platform holds the promise to replace all of the microscopes throughout the clinic into one cohesive system lowering practice equipment costs while increasing TrueVision’s overall revenue with one-time capital sales and ongoing software-based app sales (one time or subscription).

TrueVision’s 2017 focus includes surgeries in ophthalmology (i.e., cataract, refractive, glaucoma and retina), neurosurgery and orthopedics with an initial focus on spine. Its growth strategy leverages strategic partners to drive unit placements while internally developing apps to increase per unit revenue. Today, TrueVision’s OEM partners include Alcon, Leica and Aesculap, leaders in their respective areas. The Company plans to enter dentistry, cardiology, general surgery and other specialties in the future.

With approximately 60 employees, the TrueVision reached profitability in 2016 and continues to grow rapidly. Led by a strong management team who has worked together for the last ten years, TrueVision has amassed a broad intellectual property portfolio with 20+ issued and pending patents, numerous trademarks and trade secrets, and a strong pipeline of new products and software solutions. You can find additional information about the Company at

The Company remains interested in exploring Strategic Partnerships in all areas of medicine.

Back To Top


    Lenticular Research Group

VISTA OCULAR LLCElectronic Enhancement for Presbyopia Correcting Lenses

Vista Ocular, LLC (Vista) [] is a North Canton, OH medical device Company that is developing innovative recognition technology for ophthalmic devices. A sensory component that detects the innervating ciliary muscle signals will provide the trigger for a variety of electronic lenses.

The Vista technology is unique in that the proprietary design bypasses both pupillary movement and the ciliary muscle movement—the most common trigger for current Presbyopia Correcting Intraocular Lenses (PC-IOLs) —and harnesses the muscle’s action potential to serve as the signal for accommodation. The Vista sensing device could be used with various electronic PC-IOL designs. It could be adapted for triggering a PC-Contact Lens and even a Corneal Inlay. In addition, the increased ciliary muscle tone due to activation could increase aqueous outflow, thereby enhancing performance of MIGS (Minimally Invasive Glaucoma Surgery) devices used in cataract surgery.

Since January 2015, Vista has partnered with a well-respected research, engineering and electronics company in Europe, who has taken the lead in developing Vista’s technology. Vista has also been working with a major University that has recently completed encouraging studies for the Vista device. The action potential of the ciliary muscle had never previously been recorded in humans or primates. Vista’s study demonstrated that the signal is detectable and its development team has confirmed, via electromyography in primates, that the action potential is of sufficient strength to be incorporated into the Vista design or virtually any other electronically controlled accommodative device.

The Vista technology is patented (US #8,574,295) and additional patents are pending.

Vista is currently being managed by Philip Roholt, MD, CEO, a practicing ophthalmologist for over 25 years and inventor, who has designed instruments (Storz and Rhein Medical) and published articles on refractive surgery; William Kokonaski, CTO, a materials, optics and electronics expert; and Randy McDonald, Managing Officer, and founder and president of The Magnum Group, Inc., an ophthalmic business development firm.

Vista is currently seeking Strategic Partners and raising bridge financing to fund the development and in vivo testing of a sensor system for the detection of the ciliary muscle’s action potential.

Back To Top


Previous Clients

The following companies are Clients previously served by The Magnum Group. Magnum may or may not have an ongoing retained relationship with one or more of these entities.
  • Cobalt (Ora)
  • Encore Medical (formerly NewLens)
  • XIUM, LLC.

Cataract and Intraocular Lenses
  • Acuity/Medical
  • Anteis
  • APX Ophthalmology Ltd.
  • C & C Vision (Bausch & Lomb/eyeonics)
  • Collagenesis Corporation
  • ELENZA, Inc.
  • Hanita Lenses
  • Medennium, Inc.
  • NuLens, Ltd.
  • PowerVision, Inc.
  • Prism Ophthalmics, Inc.
  • Quest Vision Technologies, Inc. (AMO)
  • Vision Solutions Technologies, Inc.
  • Xcelens

Contact Lenses
  • Coast Vision (CooperVision)
  • Euclid Systems, Inc.
  • PolyVue Technologies, Inc.
  • Sunsoft Corporation (CooperVision)
  • Visioneering Technologies, Inc.
  • Wesley Jessen (CIBA Vision)

Corneal Inlays
  • Boston Innovative Optics (AcuFocus)
  • MINU, LLC. (AcuFocus/AOS)

  • Annidis Corporation
  • e-Vision, LLC
  • Humphrey Systems, Inc. (Zeiss-Meditec)
  • Intelon Optics, Inc.
  • Konan Medical USA, Inc.
  • Laser Diagnostic Technologies
  • Massie Research (Clarity Medical Systems)
  • Nidek, Inc.
  • Notal Vision, Inc.
  • Norwood Device & Diagnostics
  • Optical Imaging, LTD
  • R. H. Burton Company
  • Rodenstock
  • Talia Technology Ltd.
  • Tracey Technologies, Inc.
  • Visual Pathways, Inc.
  • Wavefront Systems
  • WaveTec Vision Systems

  • Access Media Group, LLC (Jobson Publishing)
  • EyeXam LLC
  • Glasses Direct
  • Global Eye Ventures, LLC
  • MyEyeStore
  • NeuroVision, Inc.
  • NovaVision
  • RevitalVision, Inc.
  • RXVP, Inc.
  • Suppleye, Inc.
  • VisualPlex, Inc.

Financial & Consulting Services
  • Fortress Investment Group
  • McKenzie & Co.
  • Oxford Finance Corporation (NovaVision)
  • RoundTable Health Care Partners
  • Signet Healthcare Partners
  • Venrock

  • Cascade Ophthalmics, Inc.
  • CellPlant/Wound Healing of Oklahoma (Medtronic)
  • IntraLens, Inc./Anamed (ReVision Optics, Inc.)
  • Vidus Ocular, Inc
  • The Egg Factory, LLC
  • The Innovation Factory, Inc.

  • Biolase Technology, Inc.
  • IntraLase Corporation (AMO)
  • Laser Locators
  • LaserSight
  • Premier Laser Systems, Inc.
  • Pro Laser Medical Systems, Inc.
  • SurgiLight, Inc.
  • Technolaus Perfect Vision, GmbH
  • VISX Incorporated (AMO)

  • OmegaEye
  • Science Based Health

Pharmaceuticals & Ancillary Products
  • Accudrop
  • Aviana Molecular Technologies, LLC
  • CXL Ophthalmics, LLC
  • Klarity™
  • Mystic Pharmaceuticals, Inc.
  • NicOx S.A.
  • Optimyst Eye Care Systems, LLC
  • Rapid Pathogen Systems, Inc. (RPS)

Refractive Technologies
  • Corneal Contouring Development, LLC
  • JetLasik, Inc.
  • Norwood Abbey Eye Care
  • Oculatek
  • Refractec, Incorporated
  • Sitanium Surgical, Inc.
  • Surgical Instrument Systems, Ltd. (Ziemer Ophthalmic Systems AG)
  • Visijet, Inc. (Advanced Refractive Tech., Inc.)
  • Vision Dynamics, Inc.

  • Inoveon Corporation
  • I-Lyte, Inc.
  • OccuLogix/ Visual Sciences, Inc.
  • Retinal Implant AG
  • ScyFIX, LLC
  • Xcelerator Labs

Spectacle Lens, Supplies, Equipment & Sunglasses
  • BlueBlocker Corporation
  • CarbonFlex
  • Corning Glass
  • DAC Vision, Incorporated
  • Dynamic Eye, Inc.
  • High Performance Optics, Inc.
  • Hunter Delatour, Inc. (Optisource Intl.)
  • Huvitz Co. Ltd.
  • InnoTech, Inc.
  • NCRx Optical Solutions Inc.
  • Peak Vision
  • PixelOptics, Inc.
  • Santinelli International, Inc.
  • Shield Lenscare Products, Inc. (Hilco Wilson)
  • TENKA/Rayovac
  • The Spectacle Lens Group of Johnson & Johnson
  • WECO Optik GHbH (Briot)

  • Atrion Corporation
  • Digitalvision Systems, LLC
  • HPM Company
  • Integrity Digital Solutions
  • MediTech
  • Medtronic
  • Merck
  • Norwood Vision
  • Ocular Surgery News
  • Opto Global Holdings Pty Ltd.
  • Vision Council of America

Back to top